[1] Song JW, Lee MW, Kim HJ, Joo YD, Choi JY, Oh WY, Yoo H, Park K, Kim JW. Macrophage Targeted Theranostic Photoactivation Attenuates Plaque Inflammation and Regresses the Atheroma via Autophagy-Induced Cholesterol Efflux Assessed by Serial in vivo Imaging. Circulation 2018; (Suppl_1): A14558-A14558.
[2] Chung EJ, Mlinar LB, Nord K, Sugimoto MJ, Wonder E, Alenghat FJ, Fang Y, Tirrell M. Monocyte-Targeting Supramolecular Micellar Assemblies: A Molecular Diagnostic Tool for Atherosclerosis. Adv. Health. Mater. 2015; 3: 367-376.
[3] Sun X, Li W, Zhang X, Qi M, Zhang Z, Zhang X. E, Cui Z. In vivo targeting and imaging of atherosclerosis using multifunctional virus-like particles of simian virus 40. Nano Letters 2016; 10: 6164-6171.
[4] Peterson KR, Cottam MA, Kennedy AJ, Hasty AH. Macrophage-targeted therapeutics for metabolic disease. Trends Pharmacol. Sci. 2018; 6: 536-546.
[5] Toita R, Kawano T, Murata M, Kang JH. Anti-obesity and anti-inflammatory effects of macrophage-targeted interleukin-10-conjugated liposomes in obese mice. Biomaterials 2016; 110: 81-88.
[6] Wan X, Zhang S, Wang F, Fan W, Wu C, Mao K, Wang H, Hu Z, Yang YG, Sun T. Red blood cell-derived nanovesicles for safe and efficient macrophage-targeted drug delivery in vivo. Biomater. Sci. 2019; 1: 187-195.
[7] Singh A, Talekar M, Raikar A, Amiji M. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases. J. Control. Release. 2014; 190: 515-530.
[8] Smith BR, Ghosn EEB, Rallapalli H, Prescher JA, Larson T, Herzenberg LA, Gambhir SS. Selective uptake of single-walled carbon nanotubes by circulating monocytes for enhanced tumour delivery. Nat. Nanotechnol. 2014; 6: 481-487.
[9] Sasso MS, Lollo G, Pitorre M, Solito S, Pinton L, Valpione S, Bastiat G, Mandruzzato S, Bronte V, Marigo I. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials 2016; 96: 47-62.
[10] Amoozgar Z; Goldberg MS. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. Adv. Drug Deliver. Rev. 2015; 91: 38-51.
[11] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 7203: 436-444.
[12] Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 6917: 860-867.
[13] Freisling H, Viallon V, Lennon H, Bagnardi V, Ricci C, Butterworth AS, Sweeting M, Muller D, Romieu I, Bazelle P. Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: a multinational cohort study. BMC Med. 2020; 1: 1-11.
[14] Sørensen HT. Multimorbidity and cancer outcomes: a for more research. Clin. Epidemiol. 2013; 5: 1-2.
[15] Morishige T, Yoshioka Y, Inakura H, Tanabe A, Yao X, Narimatsu S, Monobe Y, Imazawa T, Tsunoda S-i, Tsutsumi Y, Mukai Y, Okada N, Nakagawa S. The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1β production, ROS production and endosomal rupture. Biomaterials 2010; 26: 6833-6842.
[16] Sridharan R, Cameron AR, Kelly DJ, Kearney CJ, O’Brien FJ. Biomaterial based modulation of macrophage polarization: a review and suggested design principles. Mater. Today 2015; 6: 313-325.
[17] Chen W, Shen X, Hu Y, Xu K, Ran Q, Yu Y, Dai L, Yuan Z, Huang L, Shen T, Cai K. Surface functionalization of titanium implants with chitosan-catechol conjugate for suppression of ROS-induced cells damage and improvement of osteogenesis. Biomaterials 2017; 114: 82-96.
[18] Italiani P, Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Front Immunol. 2014; 5: 514.
[19] Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013; 7446: 445-455.
[20] Eguchi, K. and R. Nagai, Islet inflammation in type 2 diabetes and physiology. J Clin Invest, 2017. 127(1): p. 14-23.
[21] Na, Y.R., et al., Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nature Reviews Gastroenterology & Hepatology, 2019. 16(9): p. 531-543.
[22] Kuznetsova, T., et al., Transcriptional and epigenetic regulation of macrophages in atherosclerosis. Nature Reviews Cardiology, 2019.
[23] DeNardo, D.G. and B. Ruffell, Macrophages as regulators of tumour immunity and immunotherapy. Nature Reviews Immunology, 2019. 19(6): p. 369-382.
[24] Locati, M., G. Curtale, and A. Mantovani, Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol, 2019.
[25] Laskar A, Eilertsen J, Li W, Yuan XM. SPION primes THP1 derived M2 macrophages towards M1-like macrophages. Biochem. Biophys. Res. Commun. 2013; 4: 737-742.
[26] Wang Q, Jiang H, Li Y, Chen W, Li H, Peng K, Zhang Z, Sun X. Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy. Biomaterials 2017; 122: 10-22.
[27] Bagalkot V, Badgeley MA, Kampfrath T, Deiuliis JA, Rajagopalan S, Maiseyeu A. Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals. J. Control. Release 2015; 217: 243-255.
[28] Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Deliver. Rev. 2004; 8: 1205-1217.
[29] Qian Y, Qiao S, Dai Y, Xu G, Dai B, Lu L, Yu X, Luo Q, Zhang Z. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. ACS Nano 2017; 9: 9536-9549.
[30] Huang Z, Zhang Z, Jiang Y, Zhang D, Chen J, Dong L, Zhang J. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J. Control. Release 2012; 2: 286-292.
[31] Liu Z, Roche PA. Macropinocytosis in phagocytes: regulation of MHC class-II-restricted antigen presentation in dendritic cells. Front. Physiol. 2015; 6: 1.
[32] Yang M, Ding J, Zhang Y, Chang F, Wang J, Gao Z, Zhuang X, Chen X. Activated macrophage-targeted dextran–methotrexate/folate conjugate prevents deterioration of collagen-induced arthritis in mice. J. Mater. Chem. B 2016; 12: 2102-2113.
[33] Heo RD, You G, Um W, Choi KY, Jeon S, Park J-S, Choi Y, Kwon S, Kim K, Kwon IC. Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis. Biomaterials 2017; 131: 15-26.
[34] Han S, Kwon T, Um JE, Haam S, Kim WJ. Highly Selective Photothermal Therapy by a Phenoxylated-Dextran-Functionalized Smart Carbon Nanotube Platform. Adv. Health. Mater. 2016; 10: 1147-1156.
[35] Foerster F, Bamberger D, Schupp J, Weilbächer M, Kaps L, Strobl S, Radi L, Diken M, Strand D, Tuettenberg A. Dextran-based therapeutic nanoparticles for hepatic drug delivery. Nanomedicine 2016; 20: 2663-2677.
[36] Bauleth-Ramos T, Shahbazi MA, Liu D, Fontana F, Correia A, Figueiredo P, Zhang H, Martins JP, Hirvonen JT, Granja P. Nutlin-3a and Cytokine Co-loaded Spermine-Modified Acetalated Dextran Nanoparticles for Cancer Chemo-Immunotherapy. Adv. Funct. Mater. 2017; 42: 1703303.
[37] Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006 Jan 15;66(2):605-12.
[38] Capobianco A, Cottone L, Monno A, Manfredi AA, Rovere-Querini P. The peritoneum: healing, immunity, and diseases. J Pathol. 2017 Oct;243(2):137-147.
[39] Capobianco A, Cottone L, Monno A, Manfredi AA, Rovere-Querini P. The peritoneum: healing, immunity, and diseases. J Pathol. 2017 Oct;243(2):137-147.
[40] Beniey M. Peritoneal Metastases from Breast Cancer: A Scoping Review. Cureus. 2019 Aug 11;11(8):e5367.
[41] Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004; 11: 1649-1659.
[42] Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 1992; 5: 351-362.
[43] May RC, Machesky LM. Phagocytosis and the actin cytoskeleton. J. Cell. Sci. 2001; Pt 6: 1061-1077.
[45] Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 2004; Pt 1: 159-69.
[46] Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 1995; 2: 389-400.
[47] Fuchs AK, Syrovets T, Haas KA, Loos C, Musyanovych A, Mailander V, Landfester K, Simmet T. Carboxyl- and amino-functionalized polystyrene nanoparticles differentially affect the polarization profile of M1 and M2 macrophage subsets. Biomaterials, 2016; 78-87.
[48] Lefkowitz DL, Lincoln JA, Lefkowitz SS, Bollen A, Moguilevsky N. Enhancement of macrophage-mediated bactericidal activity by macrophage-mannose receptor-ligand interaction. Immunol. Cell Biol. 1997; 2: 136-141.
[49] Klegeris A, Budd TC, Greenfield SA. Acetylcholinesterase-induced respiratory burst in macrophages: evidence for the involvement of the macrophage mannose-fucose receptor. BBA-Gen. 1996; Subjects 1: 159-167.
[50] Shibata Y, Metzger WJ, Myrvik QN. Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production. J. Immunol. 1997; 5: 2462-2467.
[51] Allavena P, Chieppa M, Monti P, Piemonti L. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit. Rev. Immunol. 2004; 3: 179-192.